HAE241115P100000
- 0.00
- 0.000.00%
Haemonetics Newsroom
Here's the Major Earnings Before the Open Tomorrow
Haemonetics Q2 2025 Earnings Preview
Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings
Here's Why You Should Retain DGX Stock in Your Portfolio Now
Earnings Preview: Haemonetics to Report Financial Results Pre-market on November 07
$Haemonetics(HAE.US)$ is scheduled to release its financial results pre-market on November 07 ET. Earnings PreviewAnalysts estimate $Haemonetics(HAE.US)$ to post revenue of USD342.58M for 2025Q2, up 7
Is Haemonetics (NYSE:HAE) Using Too Much Debt?
Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024
Here's Why You Should Add HAE Stock in Your Portfolio Now
Express News | Aligos Therapeutics Strengthens Senior Leadership Team With the Appointment of Hardean Achneck, Md as Chief Medical Officer
Taking A Look At Haemonetics Corporation's (NYSE:HAE) ROE
Barrington Research Maintains Outperform on Haemonetics, Maintains $108 Price Target
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $108
Barrington analyst Michael Petusky maintains $Haemonetics(HAE.US)$ with a buy rating, and maintains the target price at $108.According to TipRanks data, the analyst has a success rate of 49.8% and a
Buy Rating Affirmed for Haemonetics With Promising Growth in Hospital Segment and Strong Plasma Market Position
Is Haemonetics Corporation (HAE) an Undervalued Healthcare Stock to Buy in 2025
Haemonetics Technology Chief to Exit
Haemonetics Initiated at Buy by CL King
C.L. King Initiates Haemonetics(HAE.US) With Buy Rating, Announces Target Price $116
C.L. King analyst Kristen Stewart initiates coverage on $Haemonetics(HAE.US)$ with a buy rating, and sets the target price at $116.According to TipRanks data, the analyst has a success rate of 61.1%
BofA Securities Initiates Haemonetics(HAE.US) With Hold Rating, Announces Target Price $85
BofA Securities analyst Craig Bijou initiates coverage on $Haemonetics(HAE.US)$ with a hold rating, and sets the target price at $85.According to TipRanks data, the analyst has a success rate of 42.9%
Haemonetics Price Target Announced at $85.00/Share by B of A Securities